| 000 | 01981cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030857.0 | ||
| 008 | 131022s2012 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.24.M.Sc.2012.Ah.S | ||
| 100 | 0 | _aAhmed Samir Elsayed Selim | |
| 245 | 1 | 0 |
_aSustained release dexamethasone intravitreal implant device in management of uveitis and macular edema / _cAhmed Samir Elsayed Selim ; Supervised Omar Mohamed Elzawahry , Ayman Mohamed Khattab , Sherif Ahmed Eissa |
| 246 | 1 | 5 | _aجهاز دكساميثازون مستمر الاخراج المنزرع بالجسم الزجاجى فى مناجزة التهاب النسيج العنبى ورشح الماقولة |
| 260 |
_aCairo : _bAhmed Samir Elsayed Selim , _c2012 |
||
| 300 |
_a192 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Ophthalmology | ||
| 520 | _aThe past several years have borne witness to several advances in the treatment of macular edema. For the first time, new treatment modalities offer alternatives to observation and laser photocoagulation, namely the prolonged use of corticosteroid and anti- VEGF medications . The dexamethasone DDS is one of the most recent development and is intriguing for its therapeutic potency broad spectrum of activity, dose consistency, potential for extended duration of action, and apparently improved safety profile compared with IVTA | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aِArterio venous | |
| 653 | 4 | _aDiabetic macular edema | |
| 653 | 4 | _aEpstein barr virs | |
| 700 | 0 |
_aAyman Mohamed Khattab , _eSupervisor |
|
| 700 | 0 |
_aOmar Mohamed Elzawahry , _eSupervisor |
|
| 700 | 0 |
_aSherif Ahmed Eissa , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c43836 _d43836 |
||